We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Optimisation of the Treatment of Infectious Bursitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01406652
Recruitment Status : Unknown
Verified June 2011 by University Hospital, Geneva.
Recruitment status was:  Recruiting
First Posted : August 1, 2011
Last Update Posted : August 1, 2011
Sponsor:
Information provided by:

Study Description
Brief Summary:

Th study investigates prospectively the cost-savings related to a one-stage bursectomy (debridement, drainage and closure at the same time) versus two-stage bursectomy (debridement, left open and closure at a second time) of severe bursitis among hospitalized patients for surgical treatment of septic bursitis.

We suppose that the one-stage bursectomy reveals similar recurrence rates but is associated with a significant shortening of hospital stay, consumption of resources and increased patient satisfaction.


Condition or disease Intervention/treatment Phase
Olecranon Bursitis Patellar Bursitis Procedure: Two-stage bursectomy Phase 3

Detailed Description:

Start as single center interventional study at Geneva University Hospitals Study open for additional centres (electronic CRF) Funding on 24.6.2011 (50,000 Swiss Francs). Further demand for funding ongoing.

Spetic bursitis of knee and elbows, for which the patients are hospitalised (a substantial part of patient with failure of conservative treatement) Randomisation 1:1 (one-stage vs. two-stage).

Duration of concomitant postsurgical antibiotic therapy fixed to 7 days Exclusion of severely immuno-depressed patients.

Assessment of all costs of inpatient treatement and outpatient follow-up of included cases.

Interim analysis after ca. 100 cases planified


Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: One-stage Versus Two-stage Surgical Treatement of Infectious Bursitis
Study Start Date : May 2011
Estimated Primary Completion Date : June 2014
Estimated Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bursitis
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: One-stage bursectomy
Bursectomy with debridement and primary closure of the wound during one surgical intervention
Procedure: Two-stage bursectomy
Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
Other Name: There are no "other names"


Outcome Measures

Primary Outcome Measures :
  1. Reduction of total costs associated with one-stage treatement of septic bursitis [ Time Frame: Patients will be followed-up during hospital stay and during 2 months after discharge ]

    Onestage bursectomy is associated with significantly reduced costs of overall treatement of septic bursitis compared to a two-stage approach.

    The cost reduction concerns probably all strata of cost evaluation: surgery and anesthesiology costs, nursing costs, costs related to postoperative follow-ups, medication use, and absence from work



Secondary Outcome Measures :
  1. Equivalence of one-stage bursectomy compared to two-stage bursectomy in terms of recurrence [ Time Frame: Patients will be followed-up during hospital stay and during 2 months after discharge ]
    The one-stage approach does not only reduce costs, but harbors equally remission/cure rates of septic bursitis than the two-stage approach.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age >18 years
  2. Hospitalized for bursectomy for septic bursitis

Exclusion Criteria:

  1. Bacteraemic diseases
  2. Presence of another concomitant infection requiring antibiotics
  3. Presence of osteosynthesis material beneath the bursitis
  4. Spetic bursitis outside of the elbow or the knee
  5. Severe immune suppression (transplantation, HIV with CD4 count <200 cells/mm3, immune suppressive treatement with aequivalence of more than 15 mg of prednisone daily ).
  6. Recurrent septic bursitis episodes
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01406652


Contacts
Contact: Ilker UCKAY, MD +41 22 372 33 11 ilker.uckay@hcuge.ch
Contact: Cedric PEREZ, MD +41 22 372 33 11 cedric.perez@hcuge.ch

Locations
Switzerland
Geneva University Hospitals Recruiting
Geneva, Switzerland, 1211
Contact: Ilker UCKAY, MD    +41 22 372 33 11    ilker.uckay@hcuge.ch   
Contact: Cedric PEREZ, MD    +41 22 372 33 11    cedric.perez@hcuge.ch   
Principal Investigator: Ilker UCKAY, MD         
Sponsors and Collaborators
University Hospital, Geneva
Investigators
Principal Investigator: Ilker UCKAY, MD University Hospital, Geneva
More Information

Publications:
Responsible Party: Ilker UCKAY, MD, Geneva University Hospitals
ClinicalTrials.gov Identifier: NCT01406652     History of Changes
Other Study ID Numbers: 11-016 (NAC 11-004)
First Posted: August 1, 2011    Key Record Dates
Last Update Posted: August 1, 2011
Last Verified: June 2011

Keywords provided by University Hospital, Geneva:
septic bursitis
bursectomy
primary closure

Additional relevant MeSH terms:
Bursitis
Joint Diseases
Musculoskeletal Diseases